Merck & Co. stock enters AI drug discovery collaboration
Published on 11/20/2026 at 13:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAI partnership expands Merck's pipeline
- Merck and Isomorphic Labs will combine AI drug design with Merck's proprietary research resources.
- Isomorphic Labs will create molecular designs, while Merck will oversee development, manufacturing and commercialization.
- The agreement includes an upfront payment, milestone payments and tiered royalties.
Merck & Co. announced a strategic research collaboration with Isomorphic Labs on Friday, November 20, 2026, according to PharmaBiz. The companies will work together to discover small-molecule therapeutic candidates against an oncology target that Merck describes as strategically important.
AI joins Merck's discovery engine
Isomorphic Labs will apply its AI drug-design approach and its IsoDDE platform to generate in silico predictions and molecular designs. The collaboration will use selected proprietary data supplied by Merck, alongside the pharmaceutical group's discovery expertise and research capabilities.
Merck will take responsibility for preclinical and clinical development of products arising from the work. The company will also handle manufacturing and commercialization, giving it operational control if the research produces candidates that advance through development.
Terms link payments to progress
The agreement provides for an upfront payment to Isomorphic Labs, as well as additional payments tied to research, development, regulatory and commercial milestones. Isomorphic Labs will also receive tiered royalties on net sales. The AI company has an option to co-fund development activities in exchange for higher royalties.
George Addona, Merck's senior vice president and head of discovery, preclinical development and translational medicine, said the companies aim to combine wet-lab and dry-lab work more closely to design candidates faster. Isomorphic Labs chief research officer Sarah Skerratt said the partnership would apply the company's drug-design engine to a challenging program.
Stock trades below Xetra close
Merck & Co. stock traded at 121.62 euros on Lang & Schwarz at 13:13 CET on Friday, November 20, 2026, 0.20 percent below the Xetra close of Thursday, November 19, 2026. The quote places the market focus on the company's longer-term pipeline work, while the collaboration remains at the discovery stage and does not yet represent an approved medicine or commercial product.
Merck & Co. profile
- Company: Merck & Co., Inc.
- ISIN: US58933Y1055
- Home exchange: New York Stock Exchange
- Lang & Schwarz quote: 121.62 euros on November 20, 2026, at 13:13 CET
- Xetra close: 121.86 euros on November 19, 2026
In the broader US equity market, investors can follow the S&P 500 for the main benchmark context.
